Trial Profile
The Efficacy Assessment of Intravitreal Injection of Conbercept in Patients With Polypoidal Choroidal Vasculopathy (PCV)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Apr 2023
Price :
$35
*
At a glance
- Drugs Conbercept (Primary)
- Indications Polypoidal choroidal vasculopathy
- Focus Therapeutic Use
- Acronyms STAR
- Sponsors Chengdu Kanghong Biotech
- 11 Apr 2023 Primary endpoint (Change of Best Corrected Visual Acuity) has not been met according to result published in the Acta Ophthalmologica.
- 11 Apr 2023 Status changed from recruiting to completed according to results published in the Acta Ophthalmologica.
- 11 Apr 2023 Results from a 48-week randomized phase 4 STAR study published in the Acta Ophthalmologica.